Thursday, November 5, 2020

MissionIRNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Board Appointment of Dr. Khalid Islam

 Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with a high unmet medical need, today announced the appointment of Dr. Khalid Islam to its board of directors. Dr. Islam was the chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led its transition to a profitable company that subsequently sold for US$1 billion. In addition, he is currently an advisor to the venture group Kurma Biofund (Paris), the chairman of the board for Fennec Pharmaceuticals Inc. (NASDAQ: FENC), Gain Therapeutics Inc. and Minoryx Therapeutics SL, and serves as a director for Immunomedics Inc. (NASDAQ: IMMU), which recently maximized shareholder value through a $21 billion transaction with Gilead Sciences. “I’d like to personally welcome Dr. Islam to the board,” commented Dr. David Young, chairman and CEO of Processa Pharmaceuticals. “Dr. Islam’s extensive experience and insight within the pharmaceutical industry and his diverse perspectives will be a great addition to the board and the company.”

To view the full press release, visit https://ibn.fm/ofhbP

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products for which existing clinical evidence of efficacy has already been established for unmet or under-served medical conditions for which patients need treatment options that improve survival and/or quality of life. The company used these criteria to develop its pipeline programs in order to achieve high-value milestones effectively and efficiently using the Processa Regulatory Science approach. The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html